Therefore, the presence of SMARCA4 and TP53 mutations may influence tumor biological behavior and treatment sensitivity through multiple mechanisms, including altering the immune response, enhancing sensitivity to chemotherapy drugs, and overcoming drug resistance by inhibiting key signaling pathways through targeted therapy. Here, TP53 is linked to neoplasm.